Sample Size Determination in Clinical Trials with Multiple Endpoints

Sample Size Determination in Clinical Trials with Multiple Endpoints

Volumn , Issue , 2015, Pages 1-95

  Sozu, Takashi ^a   Sugimoto, Tomoyuki ^b   Hamasaki, Toshimitsu ^c   Evans, Scott R ^d  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925248177     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-22005-5     Document Type: Book

References (116)

1. Chuang-Stein C, Stryszak P, Dmitrienko A, Offen W (2007) Challenge of multiple co-primary endpoints: a new approach. Stat Med 26:1181-1192
2. Committee for Medicinal Products for Human Use (CHMP). Concept paper on the revision of the CHMP points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome (CPMP/EWP/785/97) (EMA/CHMP/172616/2012). EMA: London, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128217.pdf Accessed 9 June 2014
3. Cordoba G, Schwartz L, Woloshin S, Bae H, Gotzsche PC (2010) Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. Br Med J 341:c3920
4. Dmitrienko A, Tamhane AC, Bretz F (2010) Multiple testing problems in pharmaceutical statistics. Chapman & Hall/CRC, Boca Raton
5. Eaton ML, Muirhead RJ (2007) On amultiple endpoints testing problem. J Stat Plan Infer 137:3416-3429
6. Food and Drug Administration (FDA). Guidance for industry irritable bowel syndrome-clinical evaluation of drugs for treatment. Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 2012. http://www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf Accessed 9 June 2014
7. Gong J, Pinheiro JC, DeMets DL (2000) Estimating significance level and power comparisons for testing multiple endpoints in clinical trials. Control Clin Trials 21:323-329
8. Hamasaki T, Sugimoto T, Evans SR, Sozu T (2013) Sample size determination for clinical trials with co-primary outcomes: exponential event-times. Pharma Stat 12:28-34
9. Hamasaki T, Evans SR, Sugimoto T, Sozu T (2012) Power and sample size determination for clinical trials with two correlated binary relative risks. In: ENAR Spring Meeting 2010; 2012 April 1-4; Washington DC, USA
10. Hung HM,Wang SJ (2009) Some controversialmultiple testing problems in regulatory applications. J Biopharm Stat 19:1-11
11. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH tripartite guideline. Statistical principles for clinical trials. 1998. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf Accessed 9 June 2014
12. Julious SA, McIntyre NE (2012) Sample sizes for trials involving multiple correlated must-win comparisons. Pharm Stat 11:177-185
13. Kordzakhia G, Siddiqui O, Huque MF (2010) Method of balanced adjustment in testing co-primary endpoints. Stat Med 29:2055-2066
14. Offen W, Chuang-Stein C, Dmitrienko A, Littman G, Maca J, Meyerson L, Muirhead R, Stryszak P, Boddy A, Chen K, Copley-Merriman K, Dere W, Givens S, Hall D, Henry D, Jackson JD, Krishen A, Liu T, Ryder S, Sankoh AJ, Wang J, Yeh CH (2007) Multiple co-primary endpoints: medical and statistical solutions. Drug Inf J 41:31-46
15. Patel HI (1991) Comparison of treatments in a combination therapy trial. JBiopharm Stat 1:171-183
16. Senn S, Bretz F (2007) Power and sample size when multiple endpoints are considered. Pharm Stat 6:161-170
17. Song JX (2009) Sample size for simultaneous testing of rate differences in noninferiority trials with multiple endpoints. Comput Stat Data Anal 53:1201-1207
18. Sozu T, Kanou T, Hamada C, Yoshimura I (2006) Power and sample size calculations in clinical trials with multiple primary variables. Japan J Biometrics 27:83-96
19. Sozu T, Sugimoto T, Hamasaki T (2010) Sample size determination in clinical trials with multiple co-primary binary endpoints. Stat Med 29:2169-2179
20. Sozu T, Sugimoto T, Hamasaki T (2011) Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints. J Biopharm Stat 21:650-668
21. Sozu T, Sugimoto T, Hamasaki T (2012) Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables. Biometrical J 54:716-729
22. Sugimoto T, Hamasaki T, Sozu T (2011) Sample size determination in clinical trials with two correlated co-primary time-to-event endpoint. In: The 7th international conference on multiple comparison procedures, Washington DC, USA, 29 Aug-1 Sept
23. Sugimoto T, Sozu T, Hamasaki T (2012a) A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints. Pharm Stat 11:118-128
24. Sugimoto T, Hamasaki T, Sozu T, Evans SR (2012b) Sample size determination in clinical trials with two correlated time-to-event endpoints as primary contrast. In: The 6th FDA-DIA statistics forum, Washington DC, USA, 22-25 April
25. Sugimoto T, Sozu T, Hamasaki T, Evans SR (2013) A logrank test-based method for sizing clinical trials with two co-primary time-to-events endpoints. Biostatistics 14:409-421
26. Xiong C, Yu K, Gao F, Yan Y, Zhang Z (2005) Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial. Clin Trials 2:387-393
27. Berger RL (1982) Multiparameter hypothesis testing and acceptance sampling. Technometrics 24:295-300
28. Bretz F, Hothorn T,Westfall P (2011) Multiple comparisons using R. Chapman & Hall/CRC, Boca Raton
29. Chuang-Stein C, Stryszak P, Dmitrienko A, Offen W (2007) Challenge of multiple co-primary endpoints: a new approach. Stat Med 26:1181-1192
30. Eaton ML, Muirhead RJ (2007) On a multiple endpoints testing problem. J Stat Plann Infer 137:3416-3429
31. Hung HM,Wang SJ (2009) Some controversialmultiple testing problems in regulatory applications. J Biopharm Stat 19:1-11
32. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH tripartite guideline. Statistical principles for clinical trials. 1998. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf Accessed 9 June 2014
33. Johnson NL, Kotz S (1972) Distributions in statistics: continuous multivariate distributions. Wiley, New York
34. Julious SA (2009) Sample sizes for clinical trials. Chapman & Hall, Boca Raton
35. Offen W, Chuang-Stein C, Dmitrienko A, Littman G, Maca J, Meyerson L, Muirhead R, Stryszak P, Boddy A, Chen K, Copley-Merriman K, Dere W, Givens S, Hall D, Henry D, Jackson JD, Krishen A, Liu T, Ryder S, Sankoh AJ, Wang J, Yeh CH (2007) Multiple co-primary endpoints: medical and statistical solutions. Drug Inf J 41:31-46
36. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S (2006) Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14:704-715
37. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) The Donepezil Study Grou. A 24-week, double-blind, placebo-controlled trial of donepezil in patientswithAlzheimer's disease. Neurology 50:136-145
38. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M (1999) Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br Med J 318:633-640
39. Senn S, Bretz F (2007) Power and sample size when multiple endpoints are considered
40. Sozu T, Kanou T, Hamada C, Yoshimura I (2006) Power and sample size calculations in clinical trials with multiple primary variables. Japan J Biometrics 27:83-96
41. Sozu T, Sugimoto T, Hamasaki T (2011) Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints. J Biopharm Stat 21:650-668
42. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C (2000) The Galantamine USA Study Grou. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54:2269-2276
43. Westfall PH, Tobias RD,Wolfinger RD (2011) Multiple comparisons and multiple tests using SAS, 2nd edn. SAS Institute Inc
44. Cary Xiong C, Yu K, Gao F, Yan Y, Zhang Z (2005) Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial. Clin Trials 2:387-393
45. Bartlett MS (1947) The use of transformations. Biometrics 3:39-52
46. Emrich LJ, Piedmonte MR (1991) A method for generating high-dimensional multivariate binary variates. Am Stat 45:302-304
47. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 37:2115-2123
48. Johnson NL, Kotz S, Balakrishnan N (1997) Discrete multivariate distributions. Wiley, New York
49. Lydersen S, Fagerland MW, Laake P (2009) Recommended tests for association in 2 × 2 tables. Stat Med 28:1159-1175
50. Pearson K (1900) On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. Philos Mag Ser B 50:157-175
51. Prentice RL (1988) Correlated binary regression with covariates specific to each binary observarion. Biometrics 44:1033-1048
52. Sozu T, Sugimoto T, Hamasaki T (2010) Sample size determination in clinical trials with multiple co-primary binary endpoints. Stat Med 29:2169-2179
53. Sozu T, Sugimoto T, Hamasaki T (2011) Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints. J Biopharm Stat 21:650-668
54. Walters DE (1979) In defence of the arc sine approximation. Statistician 28:219-222
55. Yates F (1934) Contingency tables involving small numbers and the χ2 test. J Roy. Stat Soc Supplement. 1:217-235
56. Bartlett MS (1947) The use of transformations. Biometrics 3:39-52
57. Committee for Medicinal Products for Human Use (CHMP) (2008) Guideline on medicinal products for the treatment Alzheimer's disease and other dementias (CPMP/EWP/553/95 Rev.1). EMEA: London. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003562.pdf. Accessed 9 June 2014
58. Genz A (1992) Numerical computation of multivariate normal probabilities. J Comput Graph Stat 1:141-150
59. Miwa A, Hayter J, Kuriki S (2003) The evaluation of general non-centred orthant probabilities. J R Stat Soc B 65:223-234
60. Pearson K (1900) On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. Philos Mag, Ser B 50:157-175
61. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) The Donepezil Study Grou. A 24-week, double-blind, placebo-controlled trial of donepezil in patientswithAlzheimer's disease. Neurology 50:136-145
62. Sozu T, Sugimoto T, Hamasaki T (2010) Sample size determination in clinical trials with multiple co-primary binary endpoints. Stat Med 29:2169-2179
63. Sozu T, Sugimoto T, Hamasaki T (2011) Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints. J Biopharm Stat 21:650-668
64. Sugimoto T, Sozu T, Hamasaki T (2012) A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints. Biopharm Stat 11:118-128
65. Walters DE (1979) In defence of the arc sine approximation. Stat 28:219-222
66. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholmf AL, Jansson-Blixt C, Haglund A (2006) Donepezil in patients with severe Alzheimer's disease: double-blind, parallelgroup, placebo-controlled study. Lancet 367:1057-1065
67. Yates F (1934) Contingency tables involving small numbers and the χ2 test. J R Stat Soc, Suppl 1:217-235
68. Bretz F, Hothorn T, Westfall P (2011) Multiple comparisons using. Chapman & Hall/CRC, Boca Raton
69. Dmitrienko A, Tamhane AC, Bretz F (2010) Multiple testing problems in pharmaceutical statistics. Chapman & Hall/CRC, Boca Raton
70. Owen DB (1962) Handbook of statistical tables. Reading: Addison-Wesley Publishing Company
71. Owen DB (1965) A special case of the bivariate non-central t-distribution. Biometrika 52:437-446
72. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) The Donepezil Study Grou. A 24-week, double-blind, placebo-controlled trial of donepezil in patientswithAlzheimer's disease. Neurology 50:136-145
73. Senn S, Bretz F (2007) Power and sample size when multiple endpoints are considered. Pharma Stat 6:161-170
74. Westfall PH, Tobias RD,Wolfinger RD (2011) Multiple comparisons and multiple tests using SAS, 2nd edn. Cary: SAS Institute Inc
75. Asakura K,Hamasaki, Sugimoto T, Hayashi K, Evans S, Sozu T (2014a) Sample size determination in group-sequential clinical trials with two co-primary endpoints. Stat Med 33:2897-2913
76. Asakura K, Hamasaki T, Evans SR, Sugimoto T, Sozu T (2014b) Group-sequential designs when considering two binary outcomes as co-primary endpoints. In Chen Z et al (eds) Recent advances in applied statistics. Springer, New York 235-262
77. Bloch DA, Lai TL, Tubert-Bitter P (2001) One-sided tests in clinical trials with multiple endpoints. Biometrics 57:1039-1047
78. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT (2006) The PREMIER study: a multicenter, randomized, double blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 51:26-37
79. Clayton DG (1978) A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease. Biometrika 65:141-151
80. Dale JR (1986) Global cross-ratio models for bivariate, discrete, ordered responses. Biometrics 42:909-917
81. Dmitrienko A, Tamhane AC, Bretz F (2010) Multiple testing problems in pharmaceutical statistics. Chapman & Hall/CRC, Boca Raton
82. Dmitrienko A, Tamhabe AC (2007) Gatekeeping procedure with clinical trial applications. J Biopharm Stat 6:171-180
83. Evans SR, Hamasaki T, Hayashi K (2011) Design and data monitoring of clinical trials with coprimary benefit:risk endpoints using predicti. In: The joint meeting of the (2011) Taipei international statistical symposium and the 7th conference of Asian regional section of the IASC, Taipei, Taiwan, 16-19 Dec
84. Evans SR, Li L, Wei LJ (2007) Data monitoring in clinical trials using prediction. Drug Inf J 41:733-742
85. Frank MJ (1979) On the simultaneous associativity of F(x, y) and x + y - F(x, y). Aequationes Math 19:194-226
86. Genest C (1987) Frank's family of bivariate distribution. Biometrika 74:549-555
87. Hamasaki T, Sugimoto T, Evans SR, Sozu T (2013) Sample size determination for clinical trials with co-primary outcomes: exponential event-times. Pharm Stat 12:28-34
88. Hougaard P (1984) Life table methods for heterogeneous populations: distributions describing the heterogeneity. Biometrika 71:75-83
89. Hougaard P (1986) A class of multivariate failure time distribution. Biometrika 73:671-678
90. Jennison C, Turnbull BW (1993) Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints. Biometrics 49:741-752
91. Kosorok MR, Shi Y, DeMets DL (2004) Design and analysis of group sequential clinical trials with multiple primary endpoints. Biometrics 60:134-145
92. Lan KKG, DeMets DL (1983) Discrete sequential boundaries for clinical trials. Biometrika 70:659-663
93. Lev J (1949) The point biserial coefficient of correlation. Ann Math Stat 20:125-126
94. Li L, Evans SR, Uno H, Wei LJ (2009) Predicted interval plots (PIPS): a graphical tool for data monitoring of clinical trials. Stat Biopharm Res 1:348-355
95. Molenberghs G, Geys H, Buyse M (2001) Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes. Stat Med 20:3023-3038
96. O'Brien PC (1987) Procedure for comparing samples with multiple endpoints. Biometrics 40:1079-1087
97. O'Brien PC, Fleming TR (1979) Amultiple testing procedure for clinical trials. Biometrics 35:549-556
98. Pearson K (1909) On a new method for determining the correlation between a measured character A, and a character B. Biometrika 7:96-105
99. Plackett RL (1965) A class of bivariate distributions. J Am Stat Assoc 60:516-522
100. Pocock SJ (1977) Group sequential methods in the design and analysis of clinical trials. Biometrika 64:191-199
101. Pocock SJ (1997) Clinical trials with multiple outcomes: a statistical perspective on their design, analysis and interpretation. Control Clin Trials 18:530-545
102. Röhmel J, Gerlinger C, Benda N, Läuter J (2006) On testing simultaneously non-inferiority in two multiple primary endpoints and superiority in at least one of them. Biometrical J 48:916-933
103. Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF (2008) VALOR Trial Investigators. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: theVisipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J 156:776-782
104. Sozu T, Sugimoto T, Hamasaki T (2012) Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables. Biometrical J 54:716-729
105. Stephen B, Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P (2002) The ACCENT I study group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359:1541-1549
106. Sugimoto T, Hamasaki T, Sozu T (2011) Sample size determination in clinical trials with two correlated co-primary time-to-event endpoints. In: The 7th international conference on multiple comparison procedures, Washington DC, USA, 29 Aug -1
107. Sept Sugimoto T, Sozu T, Hamasaki T (2012a) A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints. Pharm Stat 11:118-128
108. Sugimoto T, Hamasaki T, Sozu T, Evans SR (2012b) Sample size determination in clinical trials with two correlated time-to-event endpoints as primary contrast. In: The 6th FDA-DIA statistics forum, Washington DC, USA, April 22-25
109. Sugimoto T, Sozu T, Hamasaki T, Evans SR (2013) A logrank test-based method for sizing clinical trials with two co-primary time-to-events endpoints. Biostatistics 14:409-421
110. Tamhane AC, Meta CR, Liu L (2010) Testing a primary and a secondary endpoint in a group sequential design. Biometrics 66:1174-1184
111. Tamhane AC, Wu Y, Mehta CR (2012a) Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints. Stat Med 31:2027-2040
112. Tamhane AC, Wu Y, Mehta CR (2012b) Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation. Stat Med 31:2041-2054
113. Tang DI, Gnecco C, Geller NL (1989) Design of group sequential clinical trials with multiple endpoints. J Am Stat Assoc 84:776-779
114. Tang DI, Geller NL (1999) Closed testing procedures for group sequential clinical trials with multiple endpoints. Biometrics 55:1188-1192
115. Tate RF (1954) Correlation between a discrete and a continuous variable. Point-biserial correlation. Ann Math Stat 25:603-607
116. Genz A Numerical computation of multivariate normal probabilities. J Comput Graph Stat 1:141-150 (1992)